{
  "documents": [
    {
      "id": "cluster_28_doc1",
      "content": "The recent implementation of Policy #NEURO-719 has significantly impacted coverage for experimental neurolinguistic therapy. Providers across the Connecticut network report increased claim denials for patients under 45 with chronic aphasia. The Hartford Clinic noted a 38% reduction in approved claims since March 2024, particularly affecting younger demographics seeking alternative treatments.",
      "metadata": {
        "format": "insurance_memo"
      }
    },
    {
      "id": "cluster_28_doc2",
      "content": "Patient M. Thorpe (DOB 10/22/1989) underwent intensive neurolinguistic rehabilitation at Silver Birch Neurocare Center following a cerebral venous thrombosis event on 02/14/2024. Treatment included daily transcranial magnetic stimulation sessions under Dr. Emilia Kostova. Claims submitted referenced research protocol NL-TMS-455.",
      "metadata": {
        "format": "medical_record"
      }
    },
    {
      "id": "cluster_28_doc3",
      "content": "The Neurocognitive Advancements Study (NL-TMS-455) at Yale-New Haven Hospital seeks participants aged 30-50 with post-thrombotic aphasia. Participants receive customized TMS regimens while insurers debate coverage under new neurological policy frameworks. Principal Investigator: Dr. Rajiv Mehta, r.mehta@yalenhn.org.",
      "metadata": {
        "format": "research_note"
      }
    },
    {
      "id": "cluster_28_doc4",
      "content": "Lumina Health denied claim #CT-88392 for M. Thorpe's TMS treatments, citing Policy #NEURO-719 exclusion of experimental protocols without FDA approval. The decision letter was sent to 85 Willow Street, New Haven CT on 05/01/2024. Appeals must reference Case ID 4492-331.",
      "metadata": {
        "format": "claim_form"
      }
    },
    {
      "id": "cluster_28_doc5",
      "content": "Hartford Courant reports growing controversy over neurolinguistic therapy access. Feature story highlights M. Thorpe's case (35-year-old poet) and the broader impact of insurance restrictions on young stroke survivors. Article quotes State Rep. L. Carbajal calling for policy review.",
      "metadata": {
        "format": "news_article"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_28",
    "cluster_risk": "HIGH",
    "content_summary": "Complex case linking experimental neurolinguistic therapy for post-thrombotic aphasia, policy changes (NEURO-719), research study (NL-TMS-455), and patient journey through Connecticut providers",
    "person": {
      "entities": [
        [
          "M. Thorpe",
          "NAME"
        ],
        [
          "10/22/1989",
          "BIRTHDATE"
        ],
        [
          "85 Willow Street, New Haven CT",
          "ADDRESS"
        ],
        [
          "NL-TMS-455",
          "NON_PERSONAL_ID"
        ],
        [
          "cerebral venous thrombosis",
          "MEDICAL_CONDITION"
        ],
        [
          "02/14/2024",
          "EVENT_DATE"
        ],
        [
          "Dr. Emilia Kostova",
          "PROVIDER"
        ],
        [
          "Silver Birch Neurocare Center",
          "LOCATION"
        ],
        [
          "transcranial magnetic stimulation",
          "TREATMENT"
        ],
        [
          "35-year-old poet",
          "UNIQUE_FACT"
        ],
        [
          "Case ID 4492-331",
          "NON_PERSONAL_ID"
        ]
      ]
    },
    "questions": [
      {
        "q": "What treatment protocol and research study reference were included in M. Thorpe's medical records from Silver Birch Neurocare Center?",
        "a": "Transcranial magnetic stimulation sessions under research protocol NL-TMS-455.",
        "sources": [
          "cluster_28_doc2"
        ],
        "type": "specific"
      },
      {
        "q": "What demographic impact did Policy #NEURO-719 have on neurolinguistic therapy claims in Hartford?",
        "a": "38% reduction in approved claims for patients under 45 with chronic aphasia.",
        "sources": [
          "cluster_28_doc1"
        ],
        "type": "general"
      },
      {
        "q": "Which identifying numbers (case + policy), address, and treatment protocol were involved in M. Thorpe's claim denial?",
        "a": "Case 4492-331, Policy #NEURO-719, 85 Willow Street, TMS sessions under NL-TMS-455.",
        "sources": [
          "cluster_28_doc4",
          "cluster_28_doc2"
        ],
        "type": "specific"
      },
      {
        "q": "What connections exist between Yale's research study and insurance coverage challenges for neurological treatments?",
        "a": "Study NL-TMS-455 participants face coverage denials under Policy #NEURO-719.",
        "sources": [
          "cluster_28_doc3",
          "cluster_28_doc1"
        ],
        "type": "general"
      }
    ]
  }
}